Femasys Inc - SIC # 3841 - SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS

Ticker Exchange SIC # Website Latest Ticker
FEMY Nasdaq 3841 http://www.femasys.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Femasys Inc

Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives - Apr 18th, 2024 12:30 pm
Femasys Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag - Mar 31st, 2024 1:06 pm
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update - Mar 28th, 2024 8:05 pm
Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape - Mar 21st, 2024 1:00 pm
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility - Mar 20th, 2024 12:15 pm
Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024 - Mar 13th, 2024 1:00 pm
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution - Mar 6th, 2024 2:00 pm
Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF - Feb 28th, 2024 2:00 pm
Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer - Feb 6th, 2024 1:30 pm
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women - Jan 26th, 2024 1:00 pm
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology - Jan 23rd, 2024 1:30 pm
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine - Dec 15th, 2023 1:30 pm
Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer - Nov 30th, 2023 1:30 pm
30 Countries with the Lowest Median Age in the World - Nov 28th, 2023 10:27 pm
Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch - Nov 28th, 2023 1:30 pm
20 Countries with the Highest Teenage Pregnancy Rates - Nov 23rd, 2023 8:38 pm
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc. - Nov 15th, 2023 1:30 pm
Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech - Nov 15th, 2023 12:30 pm
Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2023 and Provides Corporate Update - Nov 14th, 2023 12:00 pm
12 Best Stocks For Day Trading - Oct 30th, 2023 6:02 pm